Myelodysplastic Syndrome

Myelodysplastic Syndrome

Last Reviewed : 12/24/2020
Myelodysplastic Syndrome

The myelodysplastic syndromes (also known as MDS or myelodysplasia) are hematological (i.e., blood-related) medical conditions with ineffective production (or "dysplasia") of all blood cells.

Patients with MDS can develop severe anemia and require blood transfusions. In some cases, the disease worsens and the patient develops cytopenias (low blood counts) caused by progressive bone marrow failure. The outlook in MDS depends on the type and severity. Many people live normal lifespans with MDS.

The myelodysplastic syndromes are all disorders of the hematopoietic stem cells in the bone marrow (only related tomyeloid lineage). In MDS, hematopoiesis (i.e., blood production) is disorderly and ineffective. The number and quality of blood-forming cells decline irreversibly, further impairing blood production. The mean age of onset of MDS is 68 years.

We researched this topic for you and found the following best online resources. They are categorized into basic, advanced, and research level based on the extent of information you need. You will be taken to the respective websites by pressing on the links below.


Basic information: web md myelodysplastic syndromes mayoclinic myelodysplastic syndromes nhs uk myelodysplastic syndromes leukemia foundation myelodysplastic syndromes merck manuals(professional version) myelodysplastic syndromes cleveland clinic myelodysplastic syndromes


Advanced information: medscape myelodysplastic syndromes myelodysplastic syndromes patient myelodysplastic syndromes medline plus myelodysplastic syndromes lab teste online myelodysplastic syndromes cleveland clinic myelodysplastic syndromes upto date patient information: myelodysplastic syndromes (mds) in adults (beyond the basics) national organisation of rare diseases myelodysplastic syndromes myelodysplastic syndromes: esmo clinical practice guidelines published in 2014 – ann oncol (2014) 25 (suppl 3): iii57-iii69. authors: p. fenaux, d. haase, g. f. sanz, v. santini, c. buske radiopedia myelodysplastic syndromes


Research: maha a. badawi, linda m. vickars, jocelyn m. chase, and heather a. leitch, “red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome,” advances in hematology, vol. 2010, article id 164045, 5 pages, 2010. doi:10.1155/2010/164045 rev. bras. hematol. hemoter. vol.23 no.2 são josé do rio preto may/aug. 2001 article:myelodysplastic syndromes: histopathology as prognostic factor by maura romeo et al., valuation of transfusion-free living in mds: results of health utility interviews with patients by agota szende et al., health and quality of life outcomes20097:81 doi: 10.1186/1477-7525-7-81 udit bhaskar bhatnagar, daulath singh, alexy glazyrin, and jill moormeier, “paclitaxel induced mds and aml: a case report and literature review,” case reports in oncological medicine, vol. 2016, article id 8308179, 5 pages, 2016. doi:10.1155/2016/8308179 : qin t, castoro r, el ahdab s, jelinek j, wang x, et al. (2011) mechanisms of resistance to decitabine in the myelodysplastic syndrome. plos one 6(8):e23372. doi:10.1371/journal.pone.0023372

khodadad k, sadeghipour a, aghili n. generalized neutrophilic dermatosis: a rare presentation of myelodysplastic syndrome. indian j cancer [serial online] 2005 [cited 2016 jun 29];42:57-9. available from: rev. bras. hematol. hemoter. vol.36 no.3 são josé do rio preto may/june 2014 original articles:tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome by fernando barroso duarte et al.,

george n, santhosh vc, kumar h, gopal s. gingival enlargement in myelodysplastic syndrome. j indian soc periodontol [serial online] 2015 [cited 2016 jun 29];19:687-9. available from: gough sm, chung yj, aplan pd (2012) depletion of cytotoxic t-cells does not protect nup98-hoxd13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect. plos one 7(5): e36876. doi:10.1371/journal.pone.0036876 int. j. mol. sci. 2016, 17(6), 944; doi:10.3390/ijms17060944 review:immune mechanisms in myelodysplastic syndrome by andreas glenthøj et al., int. j. mol. sci. 2015, 16(1), 966-989; doi:10.3390/ijms16010966 review : potential relationship between inadequate response to dna damage and development of myelodysplastic syndrome by ting zhou et al.,


Other helpful resources(support groups): mds foundation


Related videos: myelodysplastic syndromes what is mds (myelodysplastic syndromes)? the natural history of myelodysplastic syndromes (intermediate level) myelodysplastic syndrome causes and treatment myelodysplastic syndrome | dr. tony talebi discusses myelodysplastic syndrome 6th lecture myelodysplastic syndromes neoplasms what is new in treatment research for myelodysplastic syndrome?


Presentations/quiz/newspaper articles: global myelodysplastic syndrome pipeline report 2016 - pipeline review of 92 therapeutic companies - research and markets

Please leave your comments:

Related Articles